Celexorbio
Oakland, US · 1 known investors
Celexor Bio develops monoclonal antibody therapeutics targeting plasmacytoid dendritic cells to treat severe autoimmune and inflammatory disorders by interrupting the inflammatory cascade at its source. The company's lead candidate, CLXR-901, is designed to deplete pathological pDCs and modify disease progression in underserved patient populations.
BiotechDigital HealthMedical Devices